111 INC

YI stock represents ownership in 111, Inc., a China-based digital healthcare platform that connects pharmacies, patients, and healthcare providers through online and offline channels. The company operates an e-commerce platform for pharmaceuticals and healthcare products, along with digital health services. YI is listed on the Nasdaq Global Market under the ticker YI.

111, Inc. operates within the digital healthcare and pharmaceutical distribution industry. Its business spans online pharmacy retail, B2B pharmaceutical supply chain services, and internet-based healthcare solutions. The company primarily serves the Chinese market, integrating technology with healthcare logistics and services.

The 52-week range for YI stock fluctuates based on market conditions and company developments. For the most current 52-week high and low, please refer to the latest YI data displayed on this page. This range can help investors understand the stock's price volatility over the past year.

To buy YI stock, you need a brokerage account that offers access to U.S. stock exchanges. Once your account is funded, you can place a buy order for YI shares during market hours or via extended trading sessions, depending on your broker's offerings. Ensure you review your broker's fees and trading policies before executing a trade.

Evaluating YI's valuation involves analyzing metrics such as price-to-sales, price-to-book, and enterprise value multiples, as the company may not have consistent earnings. Comparing these ratios with peers in the digital healthcare sector and considering growth prospects can provide context. For current valuation metrics, refer to the latest YI data on this page.

Investing in YI carries risks including regulatory changes in China's healthcare and e-commerce sectors, intense competition, and the company's history of net losses. Additionally, exposure to foreign markets, currency fluctuations, and reliance on third-party logistics partners could impact operations. Investors should review YI's SEC filings for a comprehensive risk discussion.